Don_J
July 19, 2012, 1:47am
1
Convergence Pharma in Cambridge England issued a press release today that pertains to early trial success in calcium channel pain blocking:
http://www.prnewswire.com/news-releases/convergence-pharmaceuticals-announces-successful-completion-of-phase-i-for-cnv2197944-and-plans-phase-ii-studies-in-neuropathic-pain-162833166.html
Convergence is also in early stage trials for a sodium channel blocker - so the above early promise with calcium channels is potentially indirectly good news for the prospects of their early stage trials with sodium channel blockers.
I really wonder if the sodium blocker would work with our issues. All of this is amazing news. Good luck to all the researchers.
Don_J
July 22, 2012, 2:34am
4
Here's the latest on the NaV 1.7 sodium channel blocker candidate by Convergence:
http://www.convergencepharma.com/index.asp?page_id=28
The NaV 1.7 sodium channel is suspected as the main culprit for erythromelalgia symptoms.